A US Food and Drug Administration panel’s review of two opioid-containing products on 15 January suggests sponsors face a high bar in bringing new formulations to market under the agency’s emerging benefit/risk framework for the category.
The anesthetic and analgesic drug products and drug safety and risk management advisory committees overwhelmingly recommended against approval of





